TY  - JOUR
TI  - CSF biomarkers of Alzheimer's disease concord with amyloid-? PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
EP  - 1481
AV  - public
Y1  - 2018/11//
KW  - Amyloid PET concordance
KW  -  Amyloid-? (1?42)
KW  -  Biomarker validation
KW  -  CSF biomarkers
KW  -  Clinical progression
KW  -  Cutoffs
KW  -  Phosphorylated tau (pTau)
KW  -  Total tau (tTau)
ID  - discovery10051921
N2  - INTRODUCTION: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. METHODS: Cutoffs for Elecsys amyloid-?1-42 (A?), total tau/A?(1-42), and phosphorylated tau/A?(1-42) were defined against [18F]flutemetamol PET in Swedish BioFINDER (n = 277) and validated against [18F]florbetapir PET in Alzheimer's Disease Neuroimaging Initiative (n = 646). Clinical progression in patients with mild cognitive impairment (n = 619) was studied. RESULTS: CSF total tau/A?(1-42) and phosphorylated tau/A?(1-42) ratios were highly concordant with PET classification in BioFINDER (overall percent agreement: 90%; area under the curve: 94%). The CSF biomarker statuses established by predefined cutoffs were highly concordant with PET classification in Alzheimer's Disease Neuroimaging Initiative (overall percent agreement: 89%-90%; area under the curves: 96%) and predicted greater 2-year clinical decline in patients with mild cognitive impairment. Strikingly, tau/A? ratios were as accurate as semiquantitative PET image assessment in predicting visual read-based outcomes. DISCUSSION: Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer's disease diagnosis.
N1  - Copyright © 2018 The Authors. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
IS  - 11
SP  - 1470
VL  - 14
JF  - Alzheimer's & Dementia
A1  - Hansson, O
A1  - Seibyl, J
A1  - Stomrud, E
A1  - Zetterberg, H
A1  - Trojanowski, JQ
A1  - Bittner, T
A1  - Lifke, V
A1  - Corradini, V
A1  - Eichenlaub, U
A1  - Batrla, R
A1  - Buck, K
A1  - Zink, K
A1  - Rabe, C
A1  - Blennow, K
A1  - Shaw, LM
A1  - Swedish BioFINDER study group, .
A1  - Alzheimer's Disease Neuroimaging Initiative, .
SN  - 1552-5279
UR  - https://doi.org/10.1016/j.jalz.2018.01.010
ER  -